Our Science

Unique mechanism of action

Lupuzor’s™ / P140’s unique mechanism of action involves modulating the activation of auto-reactive T-cells. Other attempts to modulate the immune response in SLE have been done further downstream in the immune cascade (see diagram above), most notably in the regulation of B-cells with little success.

However, in targeting upstream T-cell activation, Lupuzor^TM presents a novel approach in modulating this unwelcome autoimmune reaction.

This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed, leaving the immune system deleted from unwanted deleterious cells but intact as normal, beneficial immune cells are concerned.

Target diseases
Near term: Lupus • CIDP
Long term: Asthma • Gout

Taking old drugs and adapting them to develop a new more effective drug

Our proprietary peptide technology lends itself well to taking established products like Vancomycin and greatly improving their pharmacology.

Increased antibiotic and anti-fungal resistance is one of the biggest threats to global health, cost and mortality (WHO).

Despite the obvious threats, anti-infectives is a therapy area that attracts one of the lowest R&D spends in the biopharma industry: 80% of biopharma are focused on oncology and orphan drugs, while drug development for anti-infectives is shorter and less costly.

A significant problem in immunosuppressed patient are serious fungal infections.

Target diseases
Sepsis • Lower respiratory tract
Skin • Bone infections • MRSA